Oragenics (NYSE:OGEN) Research Coverage Started at StockNews.com

by · The Cerbat Gem

StockNews.com began coverage on shares of Oragenics (NYSE:OGEN – Free Report) in a report issued on Thursday morning. The firm issued a sell rating on the stock.

Oragenics Price Performance

Oragenics stock opened at $0.42 on Thursday. The company has a market cap of $1.88 million, a PE ratio of -0.05 and a beta of 0.45. Oragenics has a 12 month low of $0.38 and a 12 month high of $7.74. The company has a fifty day moving average price of $0.85 and a two-hundred day moving average price of $1.22.

Oragenics (NYSE:OGEN – Get Free Report) last announced its quarterly earnings results on Friday, August 9th. The company reported ($0.51) earnings per share for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Oragenics stock. Virtu Financial LLC bought a new position in shares of Oragenics, Inc. (NYSE:OGEN – Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned approximately 0.51% of Oragenics at the end of the most recent reporting period. 18.71% of the stock is currently owned by institutional investors and hedge funds.

Oragenics Company Profile

(Get Free Report)

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.

See Also